

The Critical Role of Cord Blood in New Medical Therapies

Écrit par Quick Specialized Healthcare Logistics

Vendredi, 12 Octobre 2018 15:29 - Mis à jour Vendredi, 12 Octobre 2018 15:41

NEW YORK, NY (PRWEB) OCTOBER 11, 2018 – Umbilical cord blood is now playing a critical role in the treatment of diseases like leukemia, lymphoma, sickle cell anemia, among others, and the medical industry has been moving toward the commercialization of these promising new therapies. Quick Specialized Healthcare Logistics' new e-book provides expert advice on ways to maintain the integrity and the viability of cord blood and derivative therapies throughout the supply chain.

The medical community is just beginning to discover the full potential of cord blood cells, and the next 3-5 years could produce some amazing breakthroughs for treating diseases once considered incurable. More and more, doctors and researchers are proving that cord blood cell transplants can replace diseased blood-forming cells with healthy ones.

Stem cells for transplants come from the blood of the umbilical cord collected after a baby is born. However, babies arrive into the world on their own time frame, so the logistics of cord blood collection and transportation must be carefully planned to ensure integrity and viability.

The e-book, [**Commercialization of Cord Blood Therapies – Logistics Challenges and Solutions**](#), written by life science logistics industry veterans David Murphy and Monroe Burgess, discusses some of the newest therapies and critical steps each organization should take for safe and secure transit:

- Conduct regular packaging tests
- Run studies that mirror real life transport scenarios
- Placement of temperature monitoring devices
- Utilize technology for timing and communications throughout transit

“With the growing number of medical therapies currently under investigation and the encouraging results, it is clear that cord blood stem cells could change the landscape of human healthcare. We are proud to partner with pharmaceutical and biotech companies that are developing these exciting new therapies and to provide them comprehensive logistics support”

David Murphy, Executive Vice President, Quick Specialized Healthcare Logistics

The Critical Role of Cord Blood in New Medical Therapies

Écrit par Quick Specialized Healthcare Logistics

Vendredi, 12 Octobre 2018 15:29 - Mis à jour Vendredi, 12 Octobre 2018 15:41

Quick Specialized Healthcare Logistics

Quick is the trusted logistics leader for the healthcare and life science industry, serving the community for over 35 years. Quick safely and quickly transports human organs and tissue for transplant or research, blood, blood products, cord blood, bone marrow, medical devices and equipment, as well as cell and gene therapies.